Doximity: Clinician Network Leader

Doximity reported FY2025 revenue of $570M (TTM ~$642M) with FY25 FCF of $267M and net margins around 33–37%, trading at ~ $4.7B market cap (~7.4x EV/Revenue, ~19x P/E). Subscription revenue comprises ~95% of total (≈$543.8M), net revenue retention ~119% and the company has executed $500M+ in buybacks, underscoring strong recurring revenue and capital returns. Key risks include pharma customer concentration and an ongoing securities class action/ disclosure/governance overhang that could pressure sentiment despite solid fundamentals.

Analysis

Doximity’s embedded workflow products create an unusually high switching cost that’s not captured by surface-level penetration metrics: once AI scribe and authorization automation touch billing and prior-auth workflows, customer inertia increases because replacement imposes direct revenue friction on health systems. That raises the upside to subscription ARPU over a multi-quarter horizon, but it also makes Doximity an attractive takeover target for larger stack players that can bundle EHR/IT contracts and undercut commercial pricing via cross-sell economics.

The legal/disclosure overhang is the dominant near-term volatility driver; discovery and depositions over the next 3–9 months are the biggest binary catalysts for share moves, while renewals among the top 10 customers and pharma budget commentary are the critical commercial readthroughs across the following 6–18 months. Structural risks — privacy/regulatory constraints on clinician-level targeting and large-tech replication of clinician-focused AI — sit on a multi-year horizon but would compress multiples quickly if they start to curtail targeted marketing ROI.

Second-order winners include specialist EHRs and staffing marketplaces that become preferred alternatives if pharma customers demand multi-source reach or metric verification; conversely, generalist platforms that lack HIPAA workflow integration will find it hard to capture share without material M&A or interoperability wins. For portfolio construction, the right framing is asymmetric: buy exposure to the subscription growth and strong FCF conversion while actively hedging legal/renewal binary risk via time-limited protection or market-neutral pairings against broad tech moves.

Key Decisions for Investors

• Core long (DOCS equity): Initiate a 2–3% portfolio position in DOCS on current levels, sizing to legal-uncertainty tolerance. Time horizon 9–18 months; thesis: continued ARPU expansion and FCF conversion lead to multiple expansion. Risk: adverse legal outcome or loss of a top pharma/health system contract can produce >30% drawdown; set a hard stop or hedge as below.
• Hedge via options (defined risk): Buy 12–18 month DOCS 20% OTM call options (for leverage) and simultaneously purchase a 6–9 month protective put ~10–15% OTM to cap tail downside through the expected discovery/deposition window. This construct targets ~3:1 upside/downside if operating performance holds while limiting idiosyncratic event risk.
• Market-neutral pair (reduce macro): Long DOCS vs short MSFT (beta-hedged, not dollar neutral) sized so that equity-market sensitivity is neutralized—use 6–12 month expiries or delta-hedged positions. Purpose: isolate vertical-clinician execution vs broad tech multiple compression; reward is outperformance if Doximity’s niche monetization continues while macro softens.
• Event hedge (short volatility spike): Buy a modest DOCS put spread expiring just after next quarterly earnings/major discovery milestone (e.g., 3–6 months) to protect the base equity position from a legal or renewal miss. Cost-efficient protection that limits downside while allowing participation in upside if catalysts resolve positively.